Requires vigilance for infections, hypersensitivity, and immunizations.
Risk Mitigation in Immunomodulatory Therapy

Serious Infections: Contraindicated in active infections; monitor for TB, opportunistic pathogens (e.g., aspergillosis). Discontinue if severe infection occurs.

Hypersensitivity: Immediate discontinuation for anaphylaxis or DRESS syndrome.

Immunizations: Avoid live vaccines; complete recommended vaccines pre-treatment.

Drug Interactions: Avoid concomitant TNF inhibitors (e.g., etanercept) or IL-1 blockers (e.g., anakinra) due to infection/neutropenia risks.

Pregnancy/Lactation: Limited data; consider placental transfer of IgG and infant immune risks.

Canakinumab(ILARIS)
Still’s Disease,Periodic Fever Syndromes
RELATED ARTICLES
/ 0
0 in total
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved